Publications by authors named "I V Sarvilina"

Interdisciplinary consensus on the use of Cereton in the treatment of central nervous system diseases with cognitive impairment of congenital and acquired genesis in children. Resolution of the interdisciplinary council of expertsXXIII All-Russian Forum "Zdravnitsa-2024".

View Article and Find Full Text PDF
Article Synopsis
  • The review aimed to assess the connection between osteoarthritis (OA) and cardiovascular diseases (CVD), focusing on their risk factors, underlying mechanisms, and the role of chronic pain in this relationship.
  • It emphasized the importance of conducting more clinical and observational studies on the efficacy and safety of chondroitin sulfate (CS), particularly its parenteral form (Chondroguard), for patients suffering from chronic pain due to OA and CVD.
  • Additionally, the review called for improved clinical guidelines for treating chronic pain in OA patients at risk for CVD, highlighting the need for strategies that enhance mobility and integrate disease-modifying osteoarthritis drugs (DMOADs) into treatment plans.
View Article and Find Full Text PDF

Objective: Retrospective comparative analysis of the use of SYSADOA preparations containing chondroitin sulfate (Chondroguard, 2 ml, 25 amp., glycosaminoglycan-peptide complex, 1 ml 25 amp., bioactive concentrate of small marine fish, 2 ml, 10 amp.

View Article and Find Full Text PDF

Today, arterial hypertension (AH) is often associated with accelerated aging. In the structure of AH in persons over 65 years of age, the most common form is isolated systolic hypertension (ISAH), the mechanisms of development of which remain unexplained. Molecular regulation of remodeling of smooth muscle cells of vessels, changes in which, along with perivascular fibrosis and endothelial dysfunction, lead to increased sensitivity to procontractile mediators and calcification, forms the basis of mechanisms of vascular aging and rigidity.

View Article and Find Full Text PDF

The molecular pharmacological effects of cytoflavin in patients with hypertensive encephalopathy (HE) and isolated systolic arterial hypertension (ISAH) have been investigated using the following methods: assessment of complaints, 24-hour arterial pressure monitoring, ultrasound diagnostics including echocardiography, measurement of lipid profiles and coagulograms, and molecular phenotyping by MALDI-TOF/TOF-MS. A combination of cytoflavin administration with standard therapy of HE and ISAH led to the most expressed return development of clinical symptoms, restoration of the hemodynamic, structural, and geometrical parameters of cardiovascular system, and normalization of the indices of lipid profiles and coagulograms in comparison to patients with HE and ISAH, which accepted only standard therapy. Molecular mechanisms of cytoflavin action have been revealed, which include control of the activity of cellular signaling pathways by means of intermolecular interactions.

View Article and Find Full Text PDF